The FDA approved the first drug for treating adults and pediatric patients with post-transplant cytomegalovirus infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for cytomegalovirus.
Read more: FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs